🇺🇸 FDA
Patent

US 11046752

Serpin fusion polypeptides and methods of use thereof

granted A61KA61K38/00

Quick answer

US patent 11046752 (Serpin fusion polypeptides and methods of use thereof) held by Inhibrx, Inc. expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/00